Hearing Loss Trial, Recruiting NCT07278843 Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT07278843
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be at least 3 years old
  • You must have been diagnosed with Usher syndrome type 1 (a condition causing profound deafness from birth, balance problems, and progressive vision loss) in both eyes, confirmed by a specific genetic test showing changes in both copies of the MYO7A gene
  • You must be covered by the French social security system

If you are also taking part in the virtual reality mobility and visual search tests, these extra conditions apply:

  • You must have enough knowledge of spoken or signed French to understand the tasks and instructions
  • You must have a cochlear implant that allows you to hear and understand spoken instructions during the virtual reality test, and score at least 20 out of 25 on a basic memory and thinking assessment
  • You must be between 18 and 75 years old

Who may not be able to join:

  • You are not able to attend all of the required study visits
  • You are planning to join another experimental treatment trial at any point during this study
  • You have other eye conditions affecting your eyes beyond the vision loss related to your diagnosis (for example, a history of retinal detachment, glaucoma, or diabetic eye disease)
  • You previously took part in a specific gene therapy trial called USHSTAT (NCT01505062)
  • You are currently pregnant, recently gave birth, or are breastfeeding
  • You are currently subject to a court or government order restricting your freedom
  • You are an adult under a legal guardianship arrangement or are unable to give your own consent to participate

If you are also taking part in the virtual reality mobility and visual search tests, these extra reasons may apply:

  • Your score on the memory and thinking assessment (without vision-related questions) is 20 out of 25 or below (confirm with trial site)
  • You have a physical or mental difficulty that could interfere with moving around during the test
  • You are taking medication that could affect your movement, vision, or thinking during the study assessments (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Isabelle Audo, Pr, Centre National d'Ophtalmologie des Quinze-Vingts

Phone: +330140021430

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Registry
ClinicalTrials.gov
Start date
13 October 2025
Est. completion
1 September 2032

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Best Corrected Visual Acuity (BCVA); Electroretinography (ERG); Full-field stimulus testing (FST)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov